Palvella Therapeutics (PVLA) EBT Margin (2014 - 2024)
Palvella Therapeutics (PVLA) posted quarterly EBT Margin of 4784.91% for Q1 2024, down 398834.0% year-over-year from N/an in Q2 2023, and down 794.02% quarter-over-quarter from 535.21% in Q4 2023.
Powered by 
Analysis
Palvella Therapeutics (PVLA) EBT Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported EBT Margin for 11 consecutive years, with 4784.91% the latest figure, recorded in Q1 2024.
- In Q1 2024, EBT Margin fell 398834.0% year-over-year to 4784.91%; the TTM figure through Sep 2024 stood at 54.71% (up 3894.0% YoY), while the FY2023 annual figure was 48.28%, up 2407276.0% from the prior year.
- EBT Margin retreated to 4784.91% in Q1 2024 per PVLA's latest filing, from 535.21% in the prior quarter.
- Across five years, EBT Margin topped out at 370.89% in Q4 2020 and bottomed at 8991.97% in Q4 2022.
- Historically, EBT Margin has averaged 1705.98% across 5 years, with a median of 483.41% in 2021.
- Annual changes were most pronounced in 2022 — EBT Margin tumbled 885341 bps — and 2023, when it jumped 845676 bps.
- Palvella Therapeutics' EBT Margin stood at 370.89% in 2020, then tumbled by 137 bps to 138.56% in 2021, then slumped by 6389 bps to 8991.97% in 2022, then jumped by 94 bps to 535.21% in 2023, then plunged by 794 bps to 4784.91% in 2024.
- Business Quant data shows PVLA's EBT Margin at 4784.91% in Q1 2024, 535.21% in Q4 2023, and 63.05% in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -4,784.91% |
| Dec 31, 2023 | 1,065.51% |
| Sep 30, 2023 | -57.67% |
| Jun 30, 2023 | 12.71% |
| Mar 31, 2023 | -753.93% |
| Dec 31, 2022 | -191.04% |
| Sep 30, 2022 | -222.10% |
| Jun 30, 2022 | -329.85% |
| Mar 31, 2022 | -66.73% |
| Dec 31, 2021 | -130.34% |
| Sep 30, 2021 | -468.52% |
| Jun 30, 2021 | -510.14% |
| Mar 31, 2021 | -38.89% |
| Dec 31, 2020 | -660.79% |
| Sep 30, 2020 | -440.42% |
| Jun 30, 2020 | -40.25% |
| Mar 31, 2020 | -26.67% |
| Dec 31, 2019 | -4.46% |
| Sep 30, 2019 | -17.13% |
| Jun 30, 2019 | -220.52% |